Vol. 3 No. 2 (2023)
Reimbursement Reviews

Cariprazine (Vraylar)

Published February 8, 2023

Key Messages

  • CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses cariprazine (Vraylar), 1.5 mg, 3 mg, 4.5 mg, and 6 mg oral capsules.
  • Indication: Cariprazine is indicated as monotherapy for:
    • bipolar mania — acute management of manic or mixed episodes associated with bipolar I disorder in adults
    • bipolar depression — acute management of depressive episodes associated with bipolar I disorder in adults.